Fig. 5

Patient satisfaction with current treatment in survey respondents eligible^a for migraine preventive medication (excluding calcitonin gene-related peptide-monoclonal antibody users; n = 806). ^aPatients with  ≥  4 HD/m on average over the last 90 days and  ≥  11 (MIDAS). Users of CGRP-monoclonal antibodies are excluded. CGRP, calcitonin gene-related peptide; HD/m, headache days per month; MIDAS, Migraine Disability Assessment Score